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Two actinmbinding sites have been identified on human dystrophin by proton NMR spectroscopy of synthetic peptides corresponding to delined 
regions of the polypeptidcsequencc. These are Act&Binding Site I (ABSI ) located at residues 17-26 and Actin-Binding Site 2 (AEtS2) in the region 
oi residues 125-156. Using defined fragments of the actin amino acid sequence. ABSI has been shown to bind to actin in the region represented 
by residues 83-1 I7 and ABS2 to the C-terminal region represented by residues 350-375. These dystrophin-binding sites lie on the exposed omain 
in the uctin filament. 
Proton NMR: Dyslrophin; F-uctin; Interaction; rr-Actinin; P-Spcctrin 
1. INTRODUCTION 
Dystrophin, the protein that is absent or present in 
a modified form in Duchenne and Becker muscular 
dystrophies, respectively, is now established as a corn: 
ponent of the cytoskeletal-membrane system of skeletal 
muscle. When isolated it has been shown to be a rod-like 
molecule of length 120-180 nm [1,2]. Current immu- 
nohistochemical studies indicate that it lies in a network 
with the spectrin-like domain lying parallel to and about 
15 nm from the cytoplasmic face of the membrane and 
with the C-terminal region probably inserted in the 
membrane [3,4]. The function and location of dy- 
strophin will depend on its interaction with the other 
components of the cytoskeletal-membrane system. Our 
earlier investigations to define these interactions have 
identified an actin-binding site on the N-terminal region 
of dystrophin encompassing residues 17-26 [5]. We des- 
ignate this Actin-Binding Site 1 (ABSl). This short 
region of dystrophin shows strong homology (70% 
identity) with the amino acid sequence of the com- 
parable regions of cr-actinin [6] andp-spectrin 173. When 
the common sequence Lys-Thr-Phe-Thr, which is part 
of ABSI, is aligned the homology extends further into 
all three molecules (Fig. I). In view of this hornolt>k;y 
and the nature of the interaction of actin with a-actinin 
and B-spectrin it would be expected that further sites of 
interaction of actin on dystrophin exist. This has now 
been shown to be the case by extending our earlier 
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studies using proton NMR spectroscopy of synthetic 
peptides corresponding to regions of the dystrophin 
molecule. In this communication we provide evidence 
for a second actin-binding site on dystrophin, Actin- 
Binding Site 2 (ABS 2) and identify the two sites on 
actin to which these regions of dystrophin bind. 
2. MATERIALS AND METHODS 
Peptides were synthesised and purified as drscribcd previously [5]. 
They were checked for purity and composition by proton NMR. Actin 
was prepared as described by Levine et al. [S] and stored as the 
breeze-dried protein, Before use it was dissolved in 20 mM deutcrated 
Tris-HCI, pW 7.9, containing 50 mM KCI. 2 mM MgCI, 0,5 mM DTT 
and polymerised by allowing to stand overnight at 4°C. The peptidc 
corresponding to residues 83-l I7 of actin was isolated from the digest 
obtained after cyanogen bromide cleavage [S] and that corresponding 
to residues 3X1-375 synthesised. For spin labelling. 5 mg of peptide 
dissolved in I.5 ml G M gudnidinc hydrochloride, IO mM Tris-HCI, 
pH 8.0. was reduced overnight with a 20% molar excess of DTT. 
Excess DTT was removed by HPLC and the peak containing the 
peptide freeze-dried. The reduced peptidc was immediately rcdissolvcd 
in the guanidinc hydrochloride buffer, 5x molar excess of iodoace- 
timido-tempo (Sigma Chemical Co) added and left in the dark ovcr- 
night at room temperature. Excess pin label was removed by HPLC 
and lhe labclled peptide freeze-dried and stored in the cold. 
NMR spectroscopy ~‘1s carried oul on a Bruker SOOMHz instru- 
ment as previously described [S]. Freeze-dried peptides were dissolved 
in ?H&J buffered with 20 mM deutcratcd Tris, pH 7.9. Titrations with 
artin were carried out by the addition of small aliquots of a stock 
solution of F-actin (200 PM). 
3. RESULTS AND DISCUSSlON 
3. : . .ki~~z;~fk~:ioon qf AcrimEindL~g S:‘rc 2 (.4KZ) 
In the course of screening synthetic peptides corre- 
sponding to regions downstream from ABSL (residues 
Ptrbiislted by Efscvier Scietrce Pl~biidwrs B, V. 
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Fig, 1. Comparison of the amino acid scqucnccs of the actin binding regions of human dyslrophin (ABSI and ABSZ) with the corresponding 
segmcnls of a-aclinin [61 and P-speclrin [7]. *The corresponding sequence of chicken skeletal a-aclinin is idcnlical cxcepl al rcsiduc 172. 
17-26) we observed a specific interaction with F-actin 
by a peptide consisting of residues 128-156. Titration 
of dystrophin peptide 128-l 56 with F-actin resulted in 
the selective broadening of the resonances of a number 
of residues e.g. the aromatic signals of Trp-143 and to 
a lesser extent those of Tyr-151 (Fig. 2). From the na- 
ture of these signals and those of other side chains that 
are progressively relaxed during titration, Gin yCH?, 
Thr yCH3, Asn PCH, and CHS of Leu, Val and/or Ile 
one can infer, given the primary sequence, that the 
central segment of the peptide (residues 131-148) is in- 
volved in complex formation with F-actin. This we dcs- 
ignate Actin-Binding Site 2 (ABS2). In contrast, there 
was no evidence of F-actin binding to peptides consist- 
ing of residues 3429-3440 and 3656-3685 from the C- 
terminal region of dystrophin. The specific nature of the 
interaction with F-actin was also confirmed by the 
absence of detectable spectral effects, i.e. no evidence of 
binding (& c lo’), when the pcptide consisting of 
residues 128-156 and also the other actin-binding pep- 
tide, residues lo- 32, were titrated with bovine serum 
albumin. 
3.2. Site on actin inteructirg with Actin-Binding Site I 
(ABSI) oJdystrophin 
To confirm that the dystrophin peptide, residues 12% 
156, contained a specific actin-binding site and to inves- 
tigate the relation between ABSl and ABS2, investiga- 
tions were undertaken to identify the sites on actin that 
we~r: involved in the interactions. Ideally for this 
approach peptides (100-500 yM) representing pre- 
sumptive dystrophin-binding sites on actin should be 
titrated with dystrophin (O-100 PM). Under these con- 
ditions changes in the proton NMR spectrum of the 
actin peptides can readily be detected without spectral 
interference from the large dystrophin molecule. Unfor- 
tunately dystrophin is not yet available in the amounts 
required for this type of experiment and it is necessary 
to compromise by replacing dystrophin in such experi- 
ments with synthetic peptides representing its actin- 
binding sites. In some experiments, in order to dis- 
tinguish the signal contributions from the actin and 
dystrophin peptides, aliquots were spin-labelled at uni- 
que cysteine residues where these occurred. The pa- 
ramagnetic probe attached to one of the pair of peptides 
whose putative interaction is under investigation 
provides a sensitive read-out of the proximity of the 
probe to the interacting peptide. Spectral lines arising 
from amino acid side chains cl .5 nm from the probe 
broaden on complex formation with an isotropic dis- 
tance dependence (P from the spin label) indicating 
interaction has occurred [9]. The influence of the pa- 
45 
130 
MAGLQQTNSEKI 
1.5 7 :o 6 : 5 
PPM 
FEBS LETTERS February 1992 
140 I50 
LLSWVRQSTRNYPQVNV 
-CR3 ILE, 
1 
LEU, 
VAL 
I I 
I I 
1 I 
I I 
4.5 4.0 3 s 3.0 2.5 
PPH 
Fig. 2. Effect of F-actin on the proton NMR spectrum of human dystrophin peptide, residues 128-156. (A) 200,&I peptidc, pH 7.9. T=300K. 
(B) and (C) spectra obtained on addition of 8fiM and 16yM F-actin respectively, showing progressive relaxation ofspecifk: signals due to complex 
formation. These spectral perturbations arc directly resolved by dil%rence spectroscopy (A-C). Resonance assignments were obtained by homo- 
nuclear correlation experiments. Signals marked by * derive from low moleculnr weight impuritie!;. 
ramagnetic probe on resonances of the interacting pep- 
tide can be subsequently eliminated in situ by addition 
of a reducing agent. This provides an internal control 
for monitoring association between the peptides. In 
contrast insensitivity of the target peptide signals to the 
presence of the spin label during the titration provides 
confirmatory evidence that complex formation has not 
occurred. 
A range of actin fragments consisting of synthetic 
peptides representing residues I-18, 16-41, 29-58, 32- 
76, 96-l 17 and 350-375 as well as a peptide obtained 
by cyanogen bromide cleavage, residues 83-l 19, were 
tested for interaction with the dystrophin peptide con- 
sisting of residues IO-32 in which ABSl is located. 
These actin peptides, derived from regions exposed on 
the actin filament, have previously been used by us in 
studies on the actin-binding regions of the regulatory 
proteins, troponin I and caldesmon, as well as those of 
rnyosin subfragment I. Titration with the dystrophin 
peptide, spin labelled on Cys-IO, gave evidence of its 
interaction with the synthetic peptide corresponding to 
actin residues 96-117. The spectra illustrated in Fig. 3A 
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Fig. 3. (A) Interaction of dystrophin peptide, residues 10-32, containing ABSI with aclin peptidc corresponding to residues 9G-I 17. Two pulse 
spin echo spectrum (t=60 msec) resolving signals on the basis of J-coupling (e.g. [8]). Titration of actin pcptide residues %5-l I7 (480 PM) with 
dystrophin pcptide residues 10-32, spin-labelled at Cys-IO (?.OyM, upper trace) resulted in specific paramagnetic broadening on the signals shown. 
These distance-dependent effects imply that the molecules interact in a head to tail fashion. (6) Changes in the prolon NMR spectrum of dyslrophin 
peptidc residues 128-156 when thrated with actin peptidc residues, 350-375, spin-labelted at Cys-374. (A) 120yM dystrophin peptide alone. (6) 
120 PM dystrophin peptide with addition of 16 ,uM actin peptide results in the broadening of signals (difference spectrum. A-B) homologous Lo 
those observed in interaction with F-actin (see Fig. 2). The signals detected (A-B) OECW as a consquence both of Ihe proximity of the spin label 
and of complex formation alone. 
show that the probe on the dystrophin peptide is located 
in the vicinity of His-101 of the actin molecule and the 
side chain(s) of leucine (Leu-104, -105 and/or -110) and 
threonine (Thr-103 and -106). Similar results were ob- 
tained on titrating the same spin labelled dystrophin 
peptide with the cyanogen bromide fragment of actin, 
residues 83-119 while on addition of 1.0 mM DTT to 
the pcptide mixture the paramagnetic effects were elim- 
inated. None of the other synthetic peptides or cya- 
nogen bromide fragments of actin exhibited evidence of 
binding to dystrophin peptide residues 10-32. It was 
therefore concluded that ABSl of dystrophin interacts 
with part of the region on actin represented by residues 
83-l 17. 
This result was confirmed using the actin peptide spin 
labelled at Cys-374. It can be seen from Fig. 3l3 that 
during titration the residues perturbed by the spin label 
on the actin peptide are those of glutamine, threoninc 
and the aromatic and aliphatic hydrophobic amino 
acids of the dystrophin peptide. These are exactly the 
same residues that are perturbed when the same dy- 
strophin peptide interacts with F-actin (compare Fig. 
2). There was no evidence of dystrophin peptide 
residues 128-156 binding at the other dystrophin bind- 
ing site on actin, residues 83-l 19, or interacting with 
any other of the actin peptides in the library. We there- 
fore conclude that ABS2 of dystrophin binds to the 
C-terminal region of actin represented by residues 3SO- 
375. 
3.3. Site on actin interacting with Acrin-Binding Site 2 The two sites involved in binding dystrophin are lo- 
c A BS2) of dysrpphin cated on regions of the actin molecule that are exposed 
The spectral changes observed on the interaction of in the F-actin filament [lo]. The residues on dystrophin 
dystrophin peptide residues 128-156 with F-actin were involved in these interactions with aciin are homoio- 
found to be reproducible upon titration with the C- gous with comparable regions of the a-actinin and /% 
terminal actin peptide consisting of residues 350-375. spectrin molecules (Fig. 1). In the light of this conclu- 
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sion it is significant that antibody and cross-linking cx- 
pcriments have suggested that two sites on auatitinin 
may be involved in actin binding [ 11,12]. The regions of 
the actin molecuIe implicated in these studies are those 
which contain the sites shown directly by the proton 
NMR studies to be involved in the binding of dy- 
strophin. In view of the sequence homology in the N- 
terminal regions of a-actinin and /3-spectrin it seems 
likely that the same sites on actin i.e. those in the regions 
of residues 83-l 17 and 355-370, have the capacity to 
bind dystrophin, a-actinin or /%spectrin. If this is the 
case it raises the question as to which of these proteins 
preferentially binds to actin under conditions in which 
there is not enough actin to saturate all. 
Although our investigations indicate that the two 
sites, ABSl and ABS2, are independently identifiable it 
is not yet possible to decide at this stage if, in the intact 
molecule, they are in fact close together and form part 
of a larger contact region. In this context it is important 
to determine whether these two sites on a given dy- 
strophin molecule bind to the sites on one actin subunit. 
From the recently published three dimensional model of 
the actin molecule [lo] it appears that although the dy- 
strophin binding sites on actin are fairly close (l-1.5 
nm) they do not lie on the same side of the outer 
domain. It is of interest hat interaction of actin with the 
myosin head and the regulatory proteins also involves 
multiple sites on the outer domain of the molecule in 
F-a&in [ 131 and the binding of dystrophin to actin may 
involve further docking sites. The data available 
suggests that the arrangement of the sites on both 
proteins may enable one dystrophin molecule to interact 
with an actin monomer in each of the two strands in the 
F-actin filament. In this manner the two proteins would 
be rigidly linked in the correct conformation. An aspect 
of our current research is directed to the resolution of 
this problem. 
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